Karen S. Flatten

2.8k total citations
45 papers, 1.9k citations indexed

About

Karen S. Flatten is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Karen S. Flatten has authored 45 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 19 papers in Oncology and 6 papers in Hematology. Recurrent topics in Karen S. Flatten's work include DNA Repair Mechanisms (13 papers), PARP inhibition in cancer therapy (11 papers) and Cancer therapeutics and mechanisms (10 papers). Karen S. Flatten is often cited by papers focused on DNA Repair Mechanisms (13 papers), PARP inhibition in cancer therapy (11 papers) and Cancer therapeutics and mechanisms (10 papers). Karen S. Flatten collaborates with scholars based in United States, Canada and Australia. Karen S. Flatten's co-authors include Scott H. Kaufmann, Larry M. Karnitz, Anand G. Patel, X. Wei Meng, Guy G. Poirier, Paula A. Schneider, Kevin L. Peterson, Sun Hee Lee, Judith E. Karp and Nga T. Dai and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Karen S. Flatten

45 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karen S. Flatten United States	24	1.4k	814	226	167	158	45	1.9k
Weili Ma Taiwan	16	1.3k 0.9×	986 1.2×	348 1.5×	186 1.1×	109 0.7×	59	2.0k
Shingo Dan Japan	26	1.4k 1.0×	493 0.6×	294 1.3×	149 0.9×	184 1.2×	95	2.3k
Hong Wu China	28	2.2k 1.5×	526 0.6×	173 0.8×	133 0.8×	91 0.6×	61	2.9k
Jean‐Pierre Gillet United States	16	1.0k 0.7×	876 1.1×	231 1.0×	115 0.7×	127 0.8×	29	1.7k
Sanjeev Shangary United States	22	1.9k 1.3×	1.1k 1.4×	342 1.5×	203 1.2×	95 0.6×	30	2.9k
Noriko Yoneda‐Kato Japan	23	1.3k 0.9×	396 0.5×	192 0.8×	165 1.0×	238 1.5×	35	1.7k
Hideki Murasawa Japan	7	1.7k 1.2×	1.0k 1.2×	307 1.4×	252 1.5×	63 0.4×	13	2.2k
Wynne Aherne United Kingdom	27	1.5k 1.1×	509 0.6×	270 1.2×	157 0.9×	110 0.7×	58	2.3k
Swee Y. Sharp United Kingdom	25	2.0k 1.4×	750 0.9×	198 0.9×	287 1.7×	100 0.6×	45	2.8k
Wilberto Nieves‐Neira United States	17	1.2k 0.8×	671 0.8×	254 1.1×	138 0.8×	58 0.4×	29	1.7k

Countries citing papers authored by Karen S. Flatten

Since Specialization

Citations

This map shows the geographic impact of Karen S. Flatten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen S. Flatten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen S. Flatten more than expected).

Fields of papers citing papers by Karen S. Flatten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen S. Flatten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen S. Flatten. The network helps show where Karen S. Flatten may publish in the future.

Co-authorship network of co-authors of Karen S. Flatten

This figure shows the co-authorship network connecting the top 25 collaborators of Karen S. Flatten. A scholar is included among the top collaborators of Karen S. Flatten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen S. Flatten. Karen S. Flatten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Murthy, Guru Subramanian Guru, Antoine N. Saliba, Anikó Szabó, et al.. (2024). A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 109(9). 2864–2872. 8 indexed citations

Schroeder, Barbara, Ingrid Espinoza, Zeng Hu, et al.. (2021). Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death and Disease. 12(11). 977–977. 62 indexed citations

Vincelette, Nicole D., Husheng Ding, Amelia M. Huehls, et al.. (2019). Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo. Scientific Reports. 9(1). 3617–3617. 10 indexed citations

Hurley, Rachel M., Ksenija Nesic, Olga Kondrashova, et al.. (2018). Loss of RAD51C promoter hypermethylation confers PARP inhibitor resistance. 78(13). 1 indexed citations

Pratz, Keith W., Brian D. Koh, Anand G. Patel, et al.. (2016). Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. Clinical Cancer Research. 22(15). 3894–3902. 23 indexed citations

AlHilli, Mariam, Marc A. Becker, S. John Weroha, et al.. (2016). In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecologic Oncology. 143(2). 379–388. 49 indexed citations

Gálvez‐Peralta, Marina, Karen S. Flatten, David A. Loegering, et al.. (2014). Context-Dependent Antagonism between Akt Inhibitors and Topoisomerase Poisons. Molecular Pharmacology. 85(5). 723–734. 6 indexed citations

Huntoon, Catherine J., Karen S. Flatten, Andrea E. Wahner Hendrickson, et al.. (2013). ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status. Cancer Research. 73(12). 3683–3691. 158 indexed citations

Ding, Husheng, John S. McDonald, Seongseok Yun, et al.. (2013). Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica. 99(1). 60–69. 25 indexed citations

10.

Patel, Anand G., Silvana B. De Lorenzo, Karen S. Flatten, Guy G. Poirier, & Scott H. Kaufmann. (2012). Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro. Clinical Cancer Research. 18(6). 1655–1662. 165 indexed citations

11.

Schenk, Erin L., Brian D. Koh, Karen S. Flatten, et al.. (2012). Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro. Clinical Cancer Research. 18(19). 5364–5373. 43 indexed citations

12.

Lee, Sun Hee, X. Wei Meng, Karen S. Flatten, D A Loegering, & Scott H. Kaufmann. (2012). Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm. Cell Death and Differentiation. 20(1). 64–76. 168 indexed citations

13.

Hou, Xiaonan, Fei Huang, Joan M. Carboni, et al.. (2011). Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924. Molecular Cancer Therapeutics. 10(1). 117–125. 16 indexed citations

14.

Huntoon, Catherine J., Monica D. Nye, Liyi Geng, et al.. (2010). Heat Shock Protein 90 Inhibition Depletes LATS1 and LATS2, Two Regulators of the Mammalian Hippo Tumor Suppressor Pathway. Cancer Research. 70(21). 8642–8650. 56 indexed citations

15.

Gálvez‐Peralta, Marina, Jennifer S. Hackbarth, Karen S. Flatten, et al.. (2009). On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. Bioorganic & Medicinal Chemistry Letters. 19(15). 4459–4462. 12 indexed citations

16.

Meng, Xue, Michael P. Heldebrant, Karen S. Flatten, et al.. (2009). Protein Kinase Cβ Modulates Ligand-induced Cell Surface Death Receptor Accumulation. Journal of Biological Chemistry. 285(2). 888–902. 15 indexed citations

17.

Molina, Julian R., Scott H. Kaufmann, Joel M. Reid, et al.. (2008). Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data. Clinical Cancer Research. 14(23). 7900–7908. 41 indexed citations

18.

Gálvez‐Peralta, Marina, Nga T. Dai, David A. Loegering, et al.. (2008). Overcoming S-Phase Checkpoint-Mediated Resistance: Sequence-Dependent Synergy of Gemcitabine and 7-Ethyl-10-hydroxycamptothecin (SN-38) in Human Carcinoma Cell Lines. Molecular Pharmacology. 74(3). 724–735. 9 indexed citations

19.

Meng, Xue, Sun Hee Lee, Haiming Dai, et al.. (2007). MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis. Journal of Biological Chemistry. 282(41). 29831–29846. 97 indexed citations

20.

Karnitz, Larry M., Karen S. Flatten, Jill M. Wagner, et al.. (2005). Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival. Molecular Pharmacology. 68(6). 1636–1644. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact